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Abstract: Fallopian tube carcinoma (FTC) is considered a rare malignancy, but recent evidence 
shows that its incidence may have been underestimated. Risk-reducing salpingo-oophorectomy 
(RRSO) in breast cancer susceptibility gene (BRCA)-positive women has provided a unique oppor-
tunity to study the pathogenesis of FTC and ovarian carcinomas. Newer data now suggest that most 
high-grade serous cancers of the ovary originate in the fimbrial end of the fallopian tube. Due to 
the presumed rarity of FTC, most current and more recent ovarian cancer clinical trials have now 
included patients with FTC. The treatment guidelines recommend similar overall management and 
that the same chemotherapy regimens be used for epithelial ovarian cancers and FTC.
Keywords: high grade serous cancers, serous tubal intraepithelial carcinomas, fallopian tube 
carcinoma
Introduction
Fewer than 500 patients are diagnosed with fallopian tube carcinoma (FTC) every 
year, representing about 0.2% of cancers diagnosed in women in the United States 
annually.1 The incidence rate of FTC is between 3.72 and 4.1 per one million women 
in the United States.1,2 The incidence rate is higher in Caucasian women than in 
women of African American, Hispanic, or Asian descent.1 Recent evidence shows 
that the incidence of FTC may have been grossly underestimated.3 In this article, 
we will highlight the recent literature and understanding of the pathogenesis of FTC 
that explains the underestimation of its incidence, and the current perspectives in the 
management of FTC.
Pathogenesis
The origin of epithelial ovarian cancer (EOC) was thought to be the neoplastic trans-
formation of cells in the cortical inclusion cysts of the ovary.4–6 The incessant ovulation 
theory postulated that there is a stepwise accumulation of genetic mutations in the ovar-
ian epithelial lining as a result of repeated damage and repair during ovulation, leading 
to EOC.6–9 However, it has never been demonstrated conclusively that there exists a 
precursor lesion in the ovary that progresses to high-grade serous cancer (HGSC).10,11 
Another hypothesis is that HGSC originates, not from the surface of the ovary but, 
from the epithelial layer of the neighboring fimbrial end of the fallopian tube.3–5,8,12–27 
Newer data now suggest that HGSC of ovary, primary peritoneal carcinoma (PPC), 
and FTC have similar pathogenesis and molecular biomarkers and that these cancers 
should more accurately be called pelvic serous carcinomas.14,28 The epidemiological 
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data also support a common etiology of ovarian, fallopian, 
and primary peritoneal cancers. There are racial, ethnic, and 
geographic similarities in the incidence of these three cancers, 
and the higher incidence of all three cancers in non-Hispanic 
white women further suggests a common origin.2
In general, most epithelial cancers in the body arise as a 
consequence of a series of events and progress from a benign 
epithelium to an invasive cancer.18 A proposed stepwise 
sequence to the development of invasive cancers in the fal-
lopian tube is shown in Figure 1.4,8,16,19,29
The earliest abnormality noted in the fallopian tube 
epithelium is called secretory cell outgrowth (SCOUT). 
SCOUTs are discretely localized alterations commonly 
containing an altered expression of multiple genes within a 
histologically benign tubal epithelium. Immunohistochemis-
try shows low expression of paired box 2 (PAX2), low Ki67 
index, and, in most cases, no tumor protein p53 (TP53) gene 
mutations.19 Next, somatic tumor protein 53 (p53) muta-
tions arising from deoxyribonucleic acid (DNA) damage 
appear in the benign tubal epithelium, with foci of strong 
p53 immunostaining, termed “p53 signatures”.30 The “p53 
signature” is defined as 12 or more consecutive cells with 
strongly positive p53 nuclear staining within a benign-ap-
pearing epithelium.15,16,18 In the presence of a p53 signature, 
proliferative lesions appear, which are called serous tubal 
intraepithelial lesions (STILs)31 or transitional intraepithelial 
lesions of the tube (TILTs).22 These lesions are dysplastic and 
give rise to serous tubal intraepithelial carcinoma (STIC), 
also called tubal intraepithelial carcinoma (TIC), which is 
a precursor for invasive cancer.4,8,31 STIC is composed of 
secreting cells in the distal fallopian tube, with cytologic 
atypia, a high proliferative index, and strong nuclear staining 
for p53.17 The pathogenesis of HGSC from ovarian surface 
epithelium is unclear as a similar step-wise carcinogenic 
sequence has never been identified. Recent observations 
show that STIC may be a precursor lesion for most fallopian 
tube, ovarian, and peritoneal HGSCs.5,8,14,25
The conventional pathologic classification of pelvic 
serous cancers mostly as ovarian cancer has contributed to the 
underreporting of FTCs. FTC is diagnosed only when there 
is no mass in the ovary or endometrium.14 The presence of a 
dominant tubal mass and a precursor lesion in the fallopian 
tube is a prerequisite for classification of a tumor’s origin in 
the fallopian tube, while the presence of a precursor lesion 
is not a requirement to diagnose a tumor of ovarian origin.5 
Similarly, PPC is diagnosed only when no mass is found on 
the ovary, fallopian tube, or endometrium. The convention 
has been to classify serous tumors in the pelvis as ovarian 
cancer when the origin is unclear.3 This has led to significant 
underreporting of fallopian tube cancers as many cases of 
FTC also had tumors on the surface of the ovary and there-
fore, were classified as serous ovarian cancers.3,23
Molecular pathways
Advances in molecular diagnostics have led to the discov-
ery of different mechanisms driving the EOC histological 
subtypes.17,32 Type 1 tumors include clear cell, mucinous, 
and low-grade serous and endometrioid tumors.8,17 These 
tumors show mutations in the mismatch repair genes, 
Kirsten rat sarcoma vial oncogene homolog (KRAS), v-raf 
murine sarcoma viral oncogene homolog B (BRAF), catenin 
(cadherin-associated protein), beta 1, 88kDa (CTNNB), 
phosphatidylinositol-4,5-biphosphate 3-kinase, catalytic 
subunit alpha (PIK3CA), adenine-thymine (AT)-rich inter-
active domain-containing protein 1A (ARIDIA), protein 
phosphatase 2, regulatory subunit A, alpha (PPP2R1A), and 
phosphatase and tensin homolog (PTEN).12,17,20 These tumors 
have a slow stepwise progression from cortical inclusion 
cysts to invasive cancer.4,8,12,18 In contrast, type 2 ovarian 
tumors harbor mutations (as shown in figure 2) in the TP53 
gene and are usually HGSC or (some) high-grade endometri-
oid tumors.12,17 These tumors are aggressive, usually present 
in advanced stages, and have a worse prognosis.
Tumor suppressor p53 inactivation is detected in more 
than 95% of cases of HGSC.12 Studies reporting the p53 stain-
ing of the normal ovarian epithelium in patients with ovarian 
cancer or those at high risk of ovarian cancer (breast cancer 
susceptibility gene [BRCA]-positive) have been mixed, with 
some authors reporting the presence of p53 staining while 
others finding no evidence of p53 staining on the surface 
epithelium of the ovary.11,15,33 In BRCA-positive patients who 
underwent risk-reducing salpingo-oophorectomies (RRSO), 
a p53 signature was found in 38% of examined fallopian 
tubes, while none of the cortical inclusion cysts had a p53 
signature, suggesting a fallopian origin to these cancers.15
Gene expression profiling of HGSC has shown a close 
correlation to normal fallopian tube epithelium, rather than 
ovarian epithelium.26,34 Molecular studies have also shown 
that the different histologies of ovarian cancer have dis-
tinct gene expression profiles. While HGSC most closely 
SCOUT p53
signature STIL/TILT STIC
Invasive
cancers
Figure 1 A proposed stepwise progression to invasive cancer in the fallopian tube.
Abbreviations: p53, tumor protein 53; SCOUT, secretory cell outgrowths; STIC, 
serous tubal intraepithelial carcinoma; STIL, serous tubal intraepithelial lesion; TILT, 
transitional intraepithelial lesions of the tube.
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correlates with normal fallopian tube epithelium, mucinous 
carcinomas correlate with colonic epithelium; endometrioid 
and clear cell carcinomas correlate with the endometrium 
and carry different and specific marker genes.34 Amylase, 
alpha 2B (AMY2B) and chitinase-3-like protein 1 (CHI3L1) 
have been shown to be upregulated in serous ovarian cancer 
and normal fallopian tube epithelium. Endometrioid genes, 
like fibroblast growth factor homologous factor 9 (FHF9), 
stratifin (SFN), metallothionein 1G (MT1G), and Indian 
hedgehog (IHH), have been shown to be expressed in normal 
endometrium. Carcinoembryonic antigen-related cell adhe-
sion molecule 5 (CEACAM5), lectin, galactoside-binding, 
soluble, 4 (LGALS4), and trefoil factor 2 (TFF2) were all 
shown to be distinctly expressed in mucinous carcinomas 
and to be upregulated in normal colon.34 ARID1A mutations 
are frequent in clear cell and endometrioid ovarian cancer but 
not in HGSC.35,36 The same mutation is found in the majority 
of uterine endometrioid carcinomas.37
evidence of tubal origin of ovarian cancer
RRSO in BRCA-positive and other high-risk women has 
provided a unique opportunity to study the pathogenesis of 
ovarian carcinomas, PPC, and FTC.17,18,27,38 There has never 
been a clear precursor lesion of EOC found on the surface 
of the ovary in patients undergoing RRSO, in spite of data 
from thousands of patients at high risk of ovarian cancers 
(BRCA-positive) who have undergone this procedure. The 
Sectioning and Extensively Examining the Fimbriated End 
(SEE-FIM) protocol, used for a more detailed examination 
of the fallopian tubes in RRSO specimens, has led to an 
improved understanding of the pathogenesis of pelvis serous 
cancers.39,40
Retrospective studies
In patients with BRCA mutation who underwent RRSO, 
thorough examination of the fallopian tube revealed a 
tubal source 57%–100% of the time when a tumor was 
 identified.8,13,18,38,40,41 In unselected women undergoing RRSO, 
a tubal origin was found 36%–47% of the time.14,28  Similarly, 
in a retrospective analysis of 51 patients from a single 
institution, 56% of patients who were originally classified 
as having a PPC were found to have STIC in the fallopian 
tubes.42 In another retrospective review, six out of 76 patients 
with BRCA1 mutation undergoing RRSO were found to have 
microscopic cancers. Four of these six patients had a tumor in 
the fallopian tube, one in the ovary, and the other was in the 
peritoneal washings.43 In the same study, 78% of patients with 
BRCA mutations who had stage I to II cancers were found 
to have a dominant ovarian mass. These data suggest that 
although HGSC initiation may occur in the fallopian tube, 
tumor growth and progression may be favored in the ovary, 
which could be due to a more favorable microenvironment 
in the ovary.43
In a prospective study of 360 high-risk patients who 
underwent RRSO, the pathology review included SEE-FIM 
of the fallopian tube to identify the primary site of disease. 
In this study, there were two tubal, two ovarian, and four 
noninvasive STICs, supporting the fallopian tube as a likely 
SCOUT
p53 signature
STILT/TILT
STIC
Invasive cancer
PPC
Type 2 tumors
HGSC
Cortical
inclusion cyst
Endometrioma
cystadenoma
Borderline
tumor
Clear cell
Mucinous
Endometroid
LGSC
Type1 tumors:
Figure 2 Proposed models for the development of type 1 and type 2 tumors of the ovary.
Notes: Type 1 tumors develop from cortical inclusion cysts on the surface of the ovary. Type 2 tumors develop in the fimbriae of the adjacent fallopian tube before being 
implanted on the surface of the ovary or the adjacent peritoneum.
Abbreviations: HGSC, high-grade serous cancer; LGSC, low-grade serous cancer; p53, tumor protein 53; PPC, primary peritoneal cancer; SCOUT, secretory cell out- 
growths; STIC, serous tubal intraepithelial carcinoma; STILT, serous tubal intraepithelial lesions of the tube; TILT, transitional intraepithelial lesions of the tube.
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site of origin of many pelvic HGSCs.27 In patients who had 
HGSCs involving the ovary without evidence of a concurrent 
fallopian tube lesion, it is possible that the fallopian tube was 
not the only site of tumor initiation.
Treatment of FTC
Due to the presumed rarity of FTC and PPC, there are no large, 
prospective, randomized clinical trials exclusively evaluating 
treatment for FTC or PPC. The National Comprehensive 
Cancer Network guidelines recommend similar management, 
and the same regimens be used for EOC, FTC, and PPC.44 In 
fact, compared with the older clinical trials in ovarian cancer, 
most current and more recent ovarian cancer clinical trials have 
included patients with FTC and PPC, although they are con-
sidered distinct clinical entities.45–55 Since the current evidence 
points toward a common pathogenesis for ovarian cancer, FTC, 
and PPC, similar treatment of these cancers is likely to be the 
most appropriate management of all these tumors.
First-line treatment
The first-line treatment of ovarian cancer, FTC, and PPC is a 
combination of a platinum agent and a taxane.7,56 The combi-
nation of carboplatin and paclitaxel was compared with the 
combination of cisplatin and paclitaxel in the Gynecologic 
Oncology Group (COG) 158 trial. There was no statistical 
difference in progression-free survival (PFS) or overall sur-
vival (OS) between carboplatin and paclitaxel compared with 
cisplatin and paclitaxel; however, the carboplatin arm was 
better tolerated, with fewer nonhematologic side effects.56
The combination of dose-dense weekly paclitaxel and 
carboplatin every 3 weeks was compared with the standard 
regimen of both paclitaxel and carboplatin every 3 weeks, in 
a study done by the Japanese Gynecologic Oncology Group. 
The median PFS was longer in the dose-dense arm (28.0 
months versus [vs] 17.2 months) (hazard ratio [HR] 0.71) 
(P=0.0015). The OS at 3 years was also higher in the dose-
dense regimen group (72.1%) than in the conventional treat-
ment group (65.1%) (HR 0.75) (P=0.03) However, there were 
more hematologic toxicities and treatment discontinuations 
with the dose-dense paclitaxel, although other toxicities were 
similar in both arms.57 The recently reported update to this 
trial, with over 6 years of follow-up, showed a median overall 
survival greater than 100 months in the dose-dense arm.58
In a Phase III trial (GOG 172) evaluating intraperitoneal 
therapy, patients with optimally debulked, newly diagnosed 
ovarian cancer or PPC received intravenous paclitaxel over 
24 hours and were randomized to receive either intravenous cis-
platin or intraperitoneal cisplatin and intraperitoneal  paclitaxel. 
Although the median PFS (23.8 vs 18.3 months) and OS 
(65.6 vs 49.7 months) were longer in the intraperitoneal arm 
when compared with the intravenous arm, there were signifi-
cantly more grade 3 and 4 toxicities, including pain, fatigue, 
and gastrointestinal (GI), hematologic, and neurologic toxici-
ties, with only 42% of patients receiving all six cycles of the 
assigned intraperitoneal therapy.46  Therefore, intraperitoneal 
therapy should only be considered in patients with very good 
performance status who are willing to accept the increased 
toxicity of the regimen. The recently completed GOG 252 trial 
is evaluating a modified GOG 172 intraperitoneal regimen 
(which can be given in an outpatient setting) including intra-
peritoneal carboplatin compared with intravenous carboplatin 
and paclitaxel, and the results are pending (arm 1: IV paclitaxel, 
IV carboplatin and IV bevacizumab, arm 2: IV paclitaxel, IP 
carboplatin and IV bevacizumab, arm 3: IV placlitaxel, IP 
cisplatin, IP paclitaxel and IV bevacizumab).
The combination of docetaxel plus carboplatin59 is another 
reasonable first-line option. Due to ease of administration, 
favorable side-effect profile, long track record, and convenience 
to patients, the combination of carboplatin and paclitaxel has 
emerged as the worldwide standard of care in the first-line 
treatment of advanced ovarian cancer, FTC, and PPC.7,45
The GOG 218 and International Collaboration on Ovar-
ian Neoplasms (ICON) 7 trials evaluated the addition of 
bevacizumab to front-line chemotherapy with carboplatin 
and paclitaxel. There was improvement in PFS in both trials 
but no OS benefit.48,49 There were more GI perforations in 
the patients receiving bevacizumab; however, this was not 
statistically different. The improved PFS was only observed 
among patients receiving bevacizumab with chemotherapy 
and as extended-maintenance treatment and in high-risk 
patients (36.6 months vs 28.8 months).49
Second-line treatment
Second-line treatment is determined in part by the time since 
the prior regimen. The platinum-free interval is an important 
predictor of the response to second-line treatment.60 Patients 
whose cancer was controlled for greater than 6 months from 
the last therapy are considered to be platinum sensitive.61 
These patients are retreated with a platinum doublet, depend-
ing on their comorbidities, prior toxicities, and performance 
status. Carboplatin, in combination with paclitaxel (ICON4/
Arbeitsgemeinschaft Gynaekologische Onkologie-Ovarian 
[AGO-OVAR]-2.2), gemcitabine (Intergroup trial), or 
PEGylated liposomal doxorubicin (PLD) (Caelyx in Plati-
num Sensitive Ovarian [CALYPSO]) have all been shown 
to be reasonable options.62–65 In the CALYPSO trial, the 
combination of carboplatin and PLD was compared with 
the combination of carboplatin and paclitaxel. Although the 
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OS was not different in the two arms, patients in the PLD 
arm had a statistically significant improvement in PFS, the 
primary endpoint of the trial.64,65 The side effect profile also 
favored the PLD arm.65 Although combinations, in general, 
have shown an improvement in response rate (RR), PFS, and 
OS, there is also a higher incidence of side effects. Therefore, 
in patients with multiple comorbidities or poor performance 
status, single-agent chemotherapy is appropriate.
Patients who have a recurrence within 6 months of plati-
num treatment are considered to be platinum resistant.60,61 
Patients whose cancers progress while on treatment with 
platinum are considered to be platinum refractory, and their 
prognosis is very poor. Platinum agents are not recommended 
for these patients, and further treatment is based on underly-
ing renal function, hepatic function, and other  comorbidities. 
Patients usually receive sequential therapy with single 
agents rather than combination therapy. A Phase III trial of 
weekly paclitaxel was found to be as effective as a combina-
tion therapy of paclitaxel with carboplatin or topotecan, in 
resistant ovarian cancer.66 In a retrospective study, PLD was 
shown to prolong the platinum-free interval so that patients 
could be resensitized to a platinum agent.67 However, this 
study was small, uncontrolled, and retrospective in nature, 
and in the absence of prospective trials, no firm conclusions 
can be drawn regarding the prolongation of the platinum-free 
interval with PLD. Most single-agent regimens produce a 
RR of 10%–30%. The RRs of commonly used single-agent 
cytotoxic chemotherapies are reported in Table 1. Patients 
whose disease progresses after two or more consecutive lines 
of therapy should be considered refractory to platinum and 
are candidates for early phase clinical trials.68
Targeted agents
Like most other cancers, there has been an increased interest 
in using targeted therapies in ovarian cancer. The Gynecologic 
Oncology Group conducted multiple Phase II trials (GOG 
170 series) evaluating targeted therapies in patients with 
refractory ovarian cancer, FTC, or PPC. Most of the targeted 
therapies tested had minimal activity in these unselected 
patients. Bevacizumab, aflibercept, and olaparib have been 
tested in ovarian cancer patients and had some antitumor 
activity. Other targeted agents examined in this disease, and, 
their RRs and PFS are shown in Table 2.
Bevacizumab, a monoclonal antibody against the 
vascular endothelial growth factor (VEGF) receptor, in 
combination with chemotherapy, is useful in both the 
recurrent platinum-sensitive and in the platinum-resistant 
setting. The addition of bevacizumab to carboplatin and 
gemcitabine in platinum-sensitive, recurrent pelvic serous 
cancers has shown an improvement in RR and PFS but a 
slightly higher incidence of side effects, including hyper-
tension and arterial thrombosis;50 however, no difference 
in the OS has been noted, which may be partly due to the 
subsequent therapy with bevacizumab in the patients who 
progressed on the placebo arm. In a Phase III trial of patients 
with platinum resistant disease (AURELIA), patients were 
randomized to receive investigator-selected chemotherapy 
(weekly paclitaxel, topotecan, or PLD) with or without 
bevacizumab.69 The primary end point was Response 
Evaluation Criteria in Solid Tumors (RECIST)-defined 
PFS. Patients in the bevacizumab plus chemotherapy arm 
had a PFS of 5.7 months compared with 4 months in the 
chemotherapy-only arm (HR 0.48, 95% confidence interval 
[CI]: 0.38−0.60) (P,0.001). There were also higher RRs 
and complete responses in the bevacizumab arm. No OS 
data are available yet. There were more grade 2 or higher 
adverse events in the bevacizumab arm, including hyper-
tension, proteinuria, GI perforation, and fistula formation. 
There were also more grade 3 or higher arterial throm-
boembolic events.69 Bevacizumab has been tested in Phase 
II trials as a single agent and been found to have an RR of 
21% to 26% and a median PFS of 4.4 months to 4.7 months 
and is a reasonable option.70,71
Table 1 Response rates of single agent chemotherapies in plati-
num resistant and refractory setting
Drug Response rate Reference
Weekly paclitaxel 21% Markman et al83
Gemcitabine 19% Ferrandina et al84 
Mutch et al85
PeGylated liposomal  
doxorubicin
26% Ferrandina et al84 
Mutch et al85
Pemetrexed 21% Miller et al86
Nab-paclitaxel 23% Coleman et al87
Topotecan 20% Gordon et al52
Docetaxel 22% Rose et al88
Oral etoposide 27% Rose et al88
vinorelbine 20% Rothenberg et al89
Ifosfamide 12% Markman et al90
Altretamine 14% Alberts et al91
Abbreviation: Nab, nanoparticle albumin bound.
Table 2 Response rates and progression-free survival of selected 
targeted agents
Drug ORR PFS Reference
Cediranib 17% 5.2 months Matulonis et al92
Pazopanib 18% 17% at 6 months Friedlander et al93
Temsirolimus 9% 24% at 6 months Behbakht et al94
Alisertib 10% 1.9 months Matulonis et al95
Dasatinib 0% 21% at 6 months Schilder et al54
Patupilone 15% 3.7 months Colombo et al96
Sunitinib 8% 9.9 weeks Campos et al97
Abbreviations: ORR, overall response rate; PFS, progression-free survival.
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Aflibercept, a VEGF trap, was found to be effective in 
controlling malignant ascites in a double-blind, placebo-
controlled Phase II trial in patients who had received a median 
of four prior therapies.72 The mean time to repeat paracentesis 
was significantly longer after aflibercept, 55 days vs 23 days. 
However, there were more grade 3 and 4 side effects, includ-
ing dyspnea, fatigue, and dehydration. There were also three 
intestinal perforations with aflibercept.
Olaparib, a poly–adenosine diphosphate (ADP) ribose 
polymerase (PARP) inhibitor has shown activity in BRCA-
mutant ovarian cancer – patients with BRCA mutations 
have a defect in the DNA homologous recombination repair 
mechanism, and PARP inhibitors prevent base excision 
repair.73–75 Together, these mechanisms achieve tumor cell 
death by preventing DNA repair via two different pathways, 
a process referred to as synthetic lethality. A Phase I/II trial 
in BRCA mutation-positive patients showed an RR of 40%, 
with a response duration of 28 weeks.76 Other studies have 
shown RRs from 13% to 33%.77,78 Even in patients with 
HGSC without BRCA mutation, the RR was 24%.79 Olaparib 
has been used as maintenance therapy in platinum-sensitive 
relapsed ovarian cancer and found to prolong the PFS but 
did not add an OS benefit.80 A Phase I study of olaparib with 
cediranib, a VEGF receptor tyrosine kinase inhibitor, showed 
an RR of 44% in recurrent ovarian cancer.81
Future directions
Radical fimbriectomy followed by surveillance has been 
suggested as an alternative to surveillance alone in high-
risk BRCA-positive patients reluctant to undergo bilateral 
salpingo-oophorectomy (BSO) for risk reduction of pelvic 
serous carcinomas, due to concerns of prolonged menopause 
and other complications (like osteoporosis, vaginal atrophy, 
and decreased quality of life associated with menopause).21 
This approach would preserve the ovaries and consequently 
delay menopausal symptoms until natural menopause 
occurs. However, a microscopic spread of the tumor, from 
the fallopian tube to the ovary, may occur very early; thus, 
salpingectomy alone may be insufficient to protect against 
the development of ovarian cancer and may create a false 
sense of protection.43 Therefore further evaluation of this 
procedure, with long-term follow-up, is necessary. The early 
detection of an STIC can help in the prevention of invasive 
ovarian cancers; however, no screening techniques are cur-
rently available to detect STIC. Endometrial cytological 
testing may detect early-stage ovarian, tubal, and peritoneal 
HGSCs and may be useful for ovarian cancer screening, but 
this study needs further validation.82 The inclusion of patients 
with FTC, PPC, and HGSC of the ovary in clinical trials is 
recommended as they have similar molecular abnormalities 
and likely the same cell of origin. The better understanding of 
FTC biology will lead to improved treatment and, ultimately, 
improved outcomes in FTC, PPC, and HGSC.
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